An Interview with Dr. Brian Huber of Advanced Performance Technology

The CDC has reported a sudden twist for everyone - regardless of COVID-19 vaccination status. 

While analyzing a recent COVID-19 outbreak in Providence, Mass., in collaboration with the Commonwealth of Massachusetts Dept. of Public Health, the CDC found that 74% of fully vaccinated people had contracted the delta variant, the agency said.

The CDC has reported that both unvaccinated and vaccinated people can transmit the COVID-19 virus and its strain through this finding.

The agency put out this statement confirming its mask recommendation:

"This finding is concerning and was a pivotal discovery leading to CDC’s updated mas recommendation," the CDC said. "The masking recommendation was updated to ensure the vaccinated public would not unknowingly transmit the virus to others, including their unvaccinated or immunocompromised loved ones."

Dr. Brian Huber, CEO, and founder of Advanced Performance Technology says "Current COVID vaccines are public health necessities. However, equally important is adding additional layers of protection, particularly given widely documented evidence of viral mutations and variants". Dr. Huber and his team recently announced the availability of a self-applied COVID-19 prevention medication.  

“In addition to masking, distancing, and hand hygiene, coating the nasal passages with APTTX3 is a safe and highly effective preventative strategy that provides an added layer of protection against all types of viral infectivity including SARS-CoV-2 and any viral variant,” says Dr. Brian Huber, chief executive officer and founder of Advanced Performance Technology.

“With no reported or documented side effects, requiring no needles or injections, being scalable and able to be self-administered once or twice daily, we consider the APTTX3 formulation to be an important new tool for stabilizing the long-term battle against the COVID-19 pandemic in the USA and globally,” says Dr. Huber.

The topical FDA-registered over-the-counter first aid antibiotic ointment, APTTX3, is applied inside the nasal passages by means of a cotton tip applicator. By coating the nasal passages with the ointment, a viral barrier is formed prohibiting attachment, penetration, and growth within nasal tissues (the PRIMARY SITE OF INFECTION), thereby reducing the viral load of exposure.  The company says a single application of the ointment provides 10 to 12 hours of protection against infection. 

“Our goal is to decrease the number of viral particles that can enter into the body, and the key to controlling that is the nose - which is the primary point of entry for viruses attempting to enter the system (not through the mouth or eyes),” says Dr. Huber. “We never profess that we can stop all viruses from entering. We are attempting to eliminate most of them and decrease the individual’s load of viral exposure while allowing the individual to build up immunity to the germs his immune system comes in contact with.”

Dr. Huber says the medication’s dramatic anti-viral and antibacterial efficacy is a result of the ointment’s synergistic combination of active ingredients -- tetracycline and the proprietary APT formulation.